Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

WGS

GeneDx Holdings Corp

Dec 11 • 04:00PM ET

73.83

Dollar change +1.89
Percentage change 2.63	%

Healthcare • Health Information Services • USA • NASD

Peers: ILMN GH QDEL NTRA EXAS MYGN TWST CDNA CRSP VERV

| Held by: VTI IWM VXF IWN SCHA VTWO XHS IWC ITOT VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.17	Insider Own	19.96%	Shs Outstand	27.43M	Perf Week	-7.28%
Market Cap	2.03B	Forward P/E	150.67	EPS next Y	0.49	Insider Trans	-27.47%	Shs Float	21.99M	Perf Month	0.60%
Income	-83.50M	PEG	-	EPS next Q	0.11	Inst Own	67.00%	Short Float	10.39%	Perf Quarter	93.42%
Sales	267.23M	P/S	7.59	EPS this Y	93.74%	Inst Trans	11.80%	Short Ratio	3.71	Perf Half Y	170.64%
Book/sh	7.45	P/B	9.90	EPS next Y	250.77%	ROA	-20.21%	Short Interest	2.28M	Perf Year	4294.64%
Cash/sh	4.24	P/C	17.42	EPS next 5Y	-	ROE	-36.40%	52W Range	1.55 - 89.11	Perf YTD	2584.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-26.35%	52W High	-17.15%	Beta	2.10
Dividend TTM	-	Quick Ratio	2.27	Sales past 5Y	5.08%	Gross Margin	52.57%	52W Low	4663.23%	ATR (14)	6.27
Dividend Ex-Date	-	Current Ratio	2.41	EPS Y/Y TTM	90.31%	Oper. Margin	-20.29%	RSI (14)	50.54	Volatility	8.82% 9.03%
Employees	1000	Debt/Eq	0.57	Sales Y/Y TTM	29.41%	Profit Margin	-31.25%	Recom	2.00	Target Price	80.83
Option/Short	Yes / Yes	LT Debt/Eq	0.55	EPS Q/Q	81.29%	Payout	-	Rel Volume	0.52	Prev Close	71.94
Sales Surprise	17.88%	EPS Surprise	118.65%	Sales Q/Q	44.22%	Earnings	Oct 29 BMO	Avg Volume	615.39K	Price	73.83
SMA20	-2.10%	SMA50	7.74%	SMA200	110.20%	Trades		Volume	318,365	Change	2.63%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Nov-25-24 01:26PM	This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win (Investor's Business Daily)
Nov-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conference (Business Wire) +9.21%
Nov-19-24 08:30AM	GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover (Business Wire)
Nov-18-24 08:30AM	GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary (Business Wire)
04:35PM	Loading…
Nov-07-24 04:35PM	New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields (Business Wire)
Nov-04-24 04:35PM	GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting (Business Wire)
Oct-29-24 08:00AM	GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) +49.88%
Oct-24-24 11:10AM	Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening (Business Wire) +5.37%
Oct-08-24 08:30AM	GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns (Business Wire)
Oct-03-24 04:05PM	GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire) +5.73%
Sep-27-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.34%
Aug-12-24 04:05PM	GeneDx to Participate in Fall Investor Conferences (Business Wire)
Aug-09-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-30-24 08:57PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) -10.57% +8.60%
04:05PM	Loading…
04:05PM	GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
04:05PM	GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients (Business Wire)
Jul-12-24 12:00PM	All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 04:05PM	GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 (GlobeNewswire) +9.36%
Jul-06-24 07:00AM	7 Small-Cap Stocks With Massive Potential Returns (InvestorPlace)
Jun-10-24 08:30AM	GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients (GlobeNewswire)
Jun-05-24 07:00AM	GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients (GlobeNewswire) +13.20%
May-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-24 02:20PM	Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More (Insider Monkey) +13.52%
Apr-30-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +55.18%
Apr-29-24 08:55PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	GeneDx Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-23-24 08:30AM	GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset (GlobeNewswire) +15.50%
Apr-04-24 04:05PM	GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 (GlobeNewswire) +10.39%
09:55AM	Loading…
Mar-21-24 09:55AM	Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher (Zacks) +7.87%
Mar-14-24 08:30AM	GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics (GlobeNewswire)
Feb-26-24 04:05PM	GeneDx to Participate in 44th Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-24 08:33AM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.63%
Feb-20-24 04:26PM	GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 (GlobeNewswire)
Feb-01-24 04:30PM	GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 (GlobeNewswire)
Jan-24-24 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.98%
Jan-08-24 08:55AM	GeneDx Announces Preliminary 2023 Financial Results (GlobeNewswire) +40.36%
Dec-01-23 08:30AM	GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy (GlobeNewswire)
Nov-28-23 04:05PM	GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +12.80%
Nov-20-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -13.13%
Nov-10-23 09:55AM	Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now (Zacks) -13.61%
Nov-05-23 12:10PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 08:19AM	Q3 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM	GeneDx Holdings Corp (WGS) Reports Q3 2023 Financial Results (GuruFocus.com) -8.56%
04:05PM	GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-09-23 04:05PM	GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023 (GlobeNewswire)
Sep-22-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-23 01:01PM	Insider Sell: CEO Katherine Stueland Sells 2,675 Shares of GeneDx Holdings Corp (GuruFocus.com) -5.03%
Sep-11-23 08:00AM	GeneDx Announces Evolution of Executive Leadership Team (GlobeNewswire)
Sep-06-23 08:00AM	GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced (GlobeNewswire)
Aug-21-23 07:00AM	GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine (GlobeNewswire)
Aug-09-23 08:16AM	PacBio (PACB) Inks Research Collaboration for Genome Sequencing (Zacks) -12.63%
07:59AM	Q2 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 08:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-23 08:00AM	PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care (GlobeNewswire) -6.30%
Jul-19-23 07:05AM	GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options (GlobeNewswire) +6.48%
Jul-18-23 04:05PM	GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (GlobeNewswire)
Jun-28-23 07:00AM	GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundations Mitochondrial Medicine Symposium (GlobeNewswire) +11.53%
Jun-26-23 04:01PM	GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants (GlobeNewswire)
Jun-20-23 07:00AM	GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients (GlobeNewswire) -6.11%
May-24-23 04:05PM	GeneDx to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-23-23 07:00AM	GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations (GlobeNewswire)
May-22-23 04:05PM	GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +13.10%
May-15-23 09:35AM	Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS) (Zacks)
May-09-23 04:05PM	GeneDx Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -5.65%
May-04-23 07:00AM	GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option (GlobeNewswire)
May-03-23 01:06PM	GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders (GlobeNewswire)
Apr-28-23 06:39PM	Why GeneDx Holdings Stock Lagged the Market Today (Motley Fool) -8.44%
08:10AM	GeneDx Announces Reverse Stock Split (GlobeNewswire)
07:04AM	Daily Vickers Top Buyers & Sellers for 04/28/2023 (Argus Research)
Apr-18-23 04:05PM	GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (GlobeNewswire)
12:55PM	Shareholders Should Be Pleased With GeneDx Holdings Corp.'s (NASDAQ:WGS) Price (Simply Wall St.)
Apr-03-23 08:30AM	GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel (GlobeNewswire)
Mar-22-23 04:36PM	Why Shares of GeneDx Dropped Wednesday (Motley Fool) -16.02% -13.95%
Mar-20-23 09:07PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2022 Earnings Call Transcript (Insider Monkey) +41.30% -9.54%
08:45AM	GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease Diagnostic Odyssey (GlobeNewswire)
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-16-23 08:45AM	GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray (GlobeNewswire)
Mar-14-23 04:16PM	GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-01-23 07:30AM	GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) -5.20%
Feb-28-23 08:30AM	GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting (GlobeNewswire)
Feb-21-23 04:30PM	GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023 (GlobeNewswire) -8.42%
Feb-16-23 08:30AM	GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases (GlobeNewswire) +5.82%
Jan-31-23 04:15PM	GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering (GlobeNewswire) +5.75% -9.44%
Jan-30-23 08:30AM	GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery (GlobeNewswire)
Jan-27-23 06:00AM	GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering (GlobeNewswire) +10.26%
Jan-26-23 04:53PM	GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering (GlobeNewswire)

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stueland Katherine	Chief Executive Officer	Dec 09 '24	Option Exercise	0.00	6,547	0	66,558	Dec 11 07:19 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '24	Sale	76.37	3,661	279,598	62,897	Dec 11 07:19 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '24	Option Exercise	0.00	2,462	0	25,868	Dec 11 07:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '24	Sale	76.37	1,137	86,836	24,731	Dec 11 07:18 PM
Kevin Feeley	Officer	Dec 09 '24	Proposed Sale	76.37	1,137	86,836		Dec 09 08:06 PM
Katherine Stueland	Director	Dec 09 '24	Proposed Sale	76.37	3,661	279,598		Dec 09 08:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 01 '24	Option Exercise	0.00	718	0	23,669	Dec 03 07:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 02 '24	Sale	78.39	263	20,617	23,406	Dec 03 07:21 PM
Kevin Feeley	Officer	Dec 02 '24	Proposed Sale	78.39	263	20,617		Dec 02 08:01 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Nov 21 '24	Sale	73.76	12,019	886,568	32,932	Nov 25 06:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Nov 22 '24	Sale	76.07	9,981	759,242	22,951	Nov 25 06:21 PM
Ryan Jason	Director	Nov 19 '24	Sale	71.28	31,510	2,246,130	15,490	Nov 21 08:21 PM
Ryan Jason	Director	Nov 20 '24	Sale	69.13	15,490	1,070,749	0	Nov 21 08:21 PM
Feeley Kevin	Officer	Nov 21 '24	Proposed Sale	72.73	22,000	1,600,000		Nov 21 06:14 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Nov 18 '24	Sale	70.78	126,782	8,973,059	2,719,692	Nov 19 08:00 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Nov 15 '24	Sale	69.78	20,359	1,420,663	2,846,474	Nov 19 08:00 PM
Stueland Katherine	Chief Executive Officer	Nov 15 '24	Sale	70.48	23,108	1,628,593	82,318	Nov 19 07:05 PM
Stueland Katherine	Chief Executive Officer	Nov 18 '24	Sale	70.34	22,307	1,569,091	60,011	Nov 19 07:05 PM
Ryan Jason	Officer	Nov 19 '24	Proposed Sale	70.00	47,000	3,290,000		Nov 19 05:10 PM
Stueland Katherine	Officer	Nov 15 '24	Proposed Sale	70.02	45,415	3,180,000		Nov 15 04:58 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Oct 31 '24	Sale	75.00	865,800	64,935,000	2,866,833	Nov 04 05:01 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Oct 31 '24	Proposed Sale	81.69	1,012,941	82,747,150		Oct 31 08:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '24	Option Exercise	0.00	753	0	45,225	Oct 31 05:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '24	Sale	66.60	274	18,248	44,951	Oct 31 05:14 PM
Stueland Katherine	Chief Executive Officer	Oct 29 '24	Option Exercise	0.00	3,874	0	107,580	Oct 31 05:13 PM
Stueland Katherine	Chief Executive Officer	Oct 29 '24	Sale	66.60	2,154	143,456	105,426	Oct 31 05:13 PM
Kevin Feeley	Officer	Oct 29 '24	Proposed Sale	66.60	274	18,248		Oct 29 07:45 PM
Katherine Stueland	Officer	Oct 29 '24	Proposed Sale	66.60	2,154	143,456		Oct 29 07:44 PM
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Option Exercise	0.00	18,750	0	114,207	Sep 18 04:28 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Sale	37.59	10,501	394,733	103,706	Sep 18 04:28 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	0.00	7,197	0	47,107	Sep 18 04:26 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	37.59	2,635	99,050	44,472	Sep 18 04:26 PM
Kevin Feeley	Officer	Sep 16 '24	Proposed Sale	37.59	2,635	99,050		Sep 16 06:54 PM
Katherine Stueland	Director	Sep 16 '24	Proposed Sale	37.59	10,501	394,733		Sep 16 06:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Option Exercise	0.00	2,462	0	40,805	Sep 11 08:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Sale	33.33	895	29,830	39,910	Sep 11 08:14 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Option Exercise	0.00	6,546	0	99,096	Sep 11 08:10 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Sale	33.33	3,639	121,288	95,457	Sep 11 08:10 PM
Kevin Feeley	Officer	Sep 09 '24	Proposed Sale	33.33	895	29,830		Sep 09 09:03 PM
Katherine Stueland	Officer	Sep 09 '24	Proposed Sale	33.33	3,639	121,288		Sep 09 09:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 01 '24	Option Exercise	0.00	717	0	38,605	Sep 04 08:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 03 '24	Sale	31.71	262	8,308	38,343	Sep 04 08:10 PM
Kevin Feeley	Officer	Sep 03 '24	Proposed Sale	31.71	262	8,308		Sep 03 09:35 PM
OPKO HEALTH, INC.	10% Owner	Aug 19 '24	Sale	34.49	50,000	1,724,520	2,646,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 16 '24	Sale	34.30	50,000	1,714,850	2,696,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 15 '24	Sale	33.08	39,824	1,317,505	2,746,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 12 '24	Sale	33.95	59,787	2,029,811	2,811,783	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 13 '24	Sale	34.76	24,987	868,503	2,786,796	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 08 '24	Sale	31.82	100,000	3,182,380	2,871,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Aug 06 '24	Sale	29.35	12,994	381,427	2,971,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 31 '24	Sale	33.50	88,839	2,976,346	2,984,564	Aug 02 04:21 PM
OPKO HEALTH, INC.	10% Owner	Jul 29 '24	Sale	33.86	50,000	1,692,890	3,073,403	Jul 31 05:03 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '24	Option Exercise	0.00	3,874	0	94,704	Jul 31 04:40 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '24	Sale	33.54	2,154	72,245	92,550	Jul 31 04:40 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Option Exercise	0.00	753	0	38,162	Jul 31 04:39 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	33.54	274	9,190	37,888	Jul 31 04:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 24 '24	Sale	33.72	75,000	2,529,105	3,183,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 26 '24	Sale	33.85	60,000	2,031,258	3,123,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 23 '24	Sale	33.46	75,000	2,509,245	3,258,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 22 '24	Sale	32.61	50,000	1,630,440	3,333,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 19 '24	Sale	32.29	25,000	807,250	3,383,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 17 '24	Sale	32.93	25,000	823,188	3,408,403	Jul 19 06:46 PM
OPKO HEALTH, INC.	10% Owner	Jul 05 '24	Sale	28.24	36,118	1,020,016	3,433,403	Jul 09 04:07 PM
OPKO HEALTH, INC.	10% Owner	Jul 01 '24	Sale	26.63	50,000	1,331,700	3,508,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 02 '24	Sale	29.12	25,000	728,095	3,483,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 03 '24	Sale	28.23	14,082	397,491	3,469,521	Jul 03 04:56 PM
Casdin Eli	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,593	Jun 24 07:04 PM
Leproust Emily M.	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	8,352	Jun 24 05:42 PM
PFENNIGER RICHARD C JR	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	27,664	Jun 24 05:41 PM
RUCH JOSHUA	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,853	Jun 24 05:40 PM
Meister Keith A.	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,205	Jun 24 05:39 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 16 '24	Option Exercise	0.00	7,197	0	40,055	Jun 18 05:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 17 '24	Sale	28.31	2,646	74,908	37,409	Jun 18 05:18 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '24	Option Exercise	0.00	18,750	0	98,513	Jun 18 05:17 PM
Stueland Katherine	Chief Executive Officer	Jun 17 '24	Sale	28.31	7,683	217,506	90,830	Jun 18 05:17 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '24	Option Exercise	0.00	2,462	0	33,753	Jun 11 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	24.92	895	22,303	32,858	Jun 11 04:14 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '24	Option Exercise	0.00	6,546	0	82,415	Jun 11 04:13 PM
Stueland Katherine	Chief Executive Officer	Jun 10 '24	Sale	24.92	2,652	66,088	79,763	Jun 11 04:13 PM
Casdin Capital, LLC	Director	Jun 03 '24	Buy	20.82	100,000	2,081,640	3,063,509	Jun 05 08:45 PM
Casdin Capital, LLC	Director	Jun 04 '24	Buy	22.52	30,000	675,477	3,093,509	Jun 05 08:45 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 01 '24	Option Exercise	0.00	717	0	31,553	Jun 04 04:20 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 03 '24	Sale	20.55	262	5,384	31,291	Jun 04 04:20 PM
Casdin Capital, LLC	Director	May 29 '24	Buy	21.07	40,000	842,604	2,963,509	May 31 05:37 PM
Casdin Capital, LLC	Director	May 24 '24	Buy	20.12	144,196	2,900,906	2,905,205	May 28 08:40 PM
Casdin Capital, LLC	Director	May 28 '24	Buy	20.61	18,304	377,167	2,923,509	May 28 08:40 PM
Casdin Capital, LLC	Director	May 23 '24	Buy	19.59	7,500	146,916	2,761,009	May 28 08:40 PM
Casdin Capital, LLC	Director	May 13 '24	Buy	23.31	50,000	1,165,295	2,753,509	May 15 06:16 PM
PFENNIGER RICHARD C JR	Director	May 02 '24	Option Exercise	0.00	918	0	21,836	May 03 04:04 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '24	Option Exercise	0.00	15,496	0	82,194	Apr 30 04:30 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '24	Sale	11.04	6,325	69,808	75,869	Apr 30 04:30 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Option Exercise	0.00	3,013	0	31,940	Apr 30 04:27 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Sale	11.04	1,104	12,185	30,836	Apr 30 04:27 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 16 '24	Option Exercise	0.00	18,750	0	75,257	Mar 19 04:15 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 18 '24	Sale	10.59	8,559	90,661	66,698	Mar 19 04:15 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 16 '24	Option Exercise	0.00	5,114	0	31,525	Mar 19 04:14 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 18 '24	Sale	10.59	2,008	21,269	29,517	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 16 '24	Option Exercise	0.00	7,197	0	32,180	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	10.59	3,253	34,455	28,927	Mar 19 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WGS

GeneDx Holdings Corp

Upgrade your FINVIZ experience